Exact Mass: 386.2218836
Exact Mass Matches: 386.2218836
Found 191 metabolites which its exact mass value is equals to given mass value 386.2218836
,
within given mass tolerance error 0.01 dalton. Try search metabolite list with more accurate mass tolerance error
0.001 dalton.
Oleandolide
A 14-membererd macrolide containing ten stereocentres carrying one epoxymethano, three hydroxy and five methyl substituents. It is the aglycone of the antibiotic oleandomycin.
10,11-dihydro-20-trihydroxy-leukotriene B4
10,11-dihydro-20-trihydroxy-leukotriene B4 is the metabolite of lipid omega-oxidation of leukotriene B4 (LTB4). LTB4 is the major metabolite in neutrophil polymorphonuclear leukocytes. Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes. Leukotrienes are metabolites of arachidonic acid derived from the action of 5-LO (5-lipoxygenase). The immediate product of 5-LO is LTA4 (leukotriene A4), which is enzymatically converted into either LTB4 (leukotriene B4) by LTA4 hydrolase or LTC4 (leukotriene C4) by LTC4 synthase. The regulation of leukotriene production occurs at various levels, including expression of 5-LO, translocation of 5-LO to the perinuclear region, and phosphorylation to either enhance or inhibit the activity of 5-LO. Biologically active LTB4 is metabolized by omega-oxidation carried out by specific cytochrome P450s (CYP4F) followed by beta-oxidation from the omega-carboxy position and after CoA ester formation (PMID: 7649996, 17623009, 2853166, 6088485). Leukotrienes are eicosanoids. The eicosanoids consist of the prostaglandins (PGs), thromboxanes (TXs), leukotrienes (LTs), and lipoxins (LXs). The PGs and TXs are collectively identified as prostanoids. Prostaglandins were originally shown to be synthesized in the prostate gland, thromboxanes from platelets (thrombocytes), and leukotrienes from leukocytes, hence the derivation of their names. All mammalian cells except erythrocytes synthesize eicosanoids. These molecules are extremely potent, able to cause profound physiological effects at very dilute concentrations. All eicosanoids function locally at the site of synthesis, through receptor-mediated G-protein linked signalling pathways. 10,11-Dihydro-20-trihydroxy-leukotriene B4 is the metabolite of lipid omega-oxidation of leukotriene B4 (LTB4). LTB4 is the major metabolite in neutrophil polymorphonuclear leukocytes. Omega-oxidation is the major pathway for the catabolism of leukotriene B4 in human polymorphonuclear leukocytes. Leukotrienes are metabolites of arachidonic acid derived from the action of 5-LO (5-lipoxygenase). The immediate product of 5-LO is LTA4 (leukotriene A4), which is enzymatically converted into either LTB4 (leukotriene B4) by LTA4 hydrolase or LTC4 (leukotriene C4) by LTC4 synthase. The regulation of leukotriene production occurs at various levels, including expression of 5-LO, translocation of 5-LO to the perinuclear region and phosphorylation to either enhance or inhibit the activity of 5-LO. Biologically active LTB4 is metabolized by w-oxidation carried out by specific cytochrome P450s (CYP4F) followed by beta-oxidation from the w-carboxy position and after CoA ester formation. (PMID: 7649996, 17623009, 2853166, 6088485)
(Z)-7-[(1R,2R,3R,5S)-2-(1,2-Dihydroxy-3-oxooctyl)-3,5-dihydroxycyclopentyl]hept-5-enoic acid
N-(1-amino-3,3-dimethyl-1-oxobutan-2-yl)-1-((4-hydroxycyclohexyl)methyl)-1h-indazole-3-carboxamide
C21H30N4O3 (386.23177899999996)
1-acetyl-16-methoxy-aspidospermidine-17,21-diol|3-Methoxy-limapodin
3beta,7beta,8beta,12zeta,17-pentahydroxylabdan-16,15-olide
2-[5-[2-[2-[5-(2-hydroxypropyl)oxolan-2-yl]propanoyloxy]propyl]oxolan-2-yl]propanoic acid
2-[5-[2-[2-[5-(2-hydroxypropyl)oxolan-2-yl]propanoyloxy]propyl]oxolan-2-yl]propanoic acid
2-[5-[2-[2-[5-(2-hydroxypropyl)oxolan-2-yl]propanoyloxy]propyl]oxolan-2-yl]propanoic acid [IIN-based: Match]
2-[5-[2-[2-[5-(2-hydroxypropyl)oxolan-2-yl]propanoyloxy]propyl]oxolan-2-yl]propanoic acid [IIN-based on: CCMSLIB00000845048]
2-[5-[2-[2-[5-(2-hydroxypropyl)oxolan-2-yl]propanoyloxy]propyl]oxolan-2-yl]propanoic acid [IIN-based on: CCMSLIB00000845049]
2-[5-[2-[2-[5-(2-hydroxypropyl)oxolan-2-yl]propanoyloxy]propyl]oxolan-2-yl]propanoic acid_major
2-[5-[2-[2-[5-(2-hydroxypropyl)oxolan-2-yl]propanoyloxy]propyl]oxolan-2-yl]propanoic acid_minor
Ala Ile Pro Ser
Ala Ile Ser Pro
Ala Leu Pro Ser
Ala Leu Ser Pro
Ala Pro Ile Ser
Ala Pro Leu Ser
Ala Pro Ser Ile
Ala Pro Ser Leu
Ala Pro Thr Val
Ala Pro Val Thr
Ala Ser Ile Pro
Ala Ser Leu Pro
Ala Ser Pro Ile
Ala Ser Pro Leu
Ala Thr Pro Val
Ala Thr Val Pro
Ala Val Pro Thr
Ala Val Thr Pro
Gly Ile Pro Thr
Gly Ile Thr Pro
Gly Leu Pro Thr
Gly Leu Thr Pro
Gly Pro Ile Thr
Gly Pro Leu Thr
Gly Pro Thr Ile
Gly Pro Thr Leu
Gly Thr Ile Pro
Gly Thr Leu Pro
Gly Thr Pro Ile
Gly Thr Pro Leu
Ile Ala Pro Ser
Ile Ala Ser Pro
Ile Gly Pro Thr
Ile Gly Thr Pro
Ile Pro Ala Ser
Ile Pro Gly Thr
Ile Pro Ser Ala
Ile Pro Thr Gly
Ile Ser Ala Pro
Ile Ser Pro Ala
Ile Thr Gly Pro
Ile Thr Pro Gly
Leu Ala Pro Ser
Leu Ala Ser Pro
Leu Gly Pro Thr
Leu Gly Thr Pro
Leu Pro Ala Ser
Leu Pro Gly Thr
Leu Pro Ser Ala
Leu Pro Thr Gly
Leu Ser Ala Pro
Leu Ser Pro Ala
Leu Thr Gly Pro
Leu Thr Pro Gly
Pro Ala Ile Ser
Pro Ala Leu Ser
Pro Ala Ser Ile
Pro Ala Ser Leu
Pro Ala Thr Val
Pro Ala Val Thr
Pro Gly Ile Thr
Pro Gly Leu Thr
Pro Gly Thr Ile
Pro Gly Thr Leu
Pro Ile Ala Ser
Pro Ile Gly Thr
Pro Ile Ser Ala
Pro Ile Thr Gly
Pro Leu Ala Ser
Pro Leu Gly Thr
Pro Leu Ser Ala
Pro Leu Thr Gly
Pro Ser Ala Ile
Pro Ser Ala Leu
Pro Ser Ile Ala
Pro Ser Leu Ala
Pro Thr Ala Val
Pro Thr Gly Ile
Pro Thr Gly Leu
Pro Thr Ile Gly
Pro Thr Leu Gly
Pro Thr Val Ala
Pro Val Ala Thr
Pro Val Thr Ala
Ser Ala Ile Pro
Ser Ala Leu Pro
Ser Ala Pro Ile
Ser Ala Pro Leu
Ser Ile Ala Pro
Ser Ile Pro Ala
Ser Leu Ala Pro
Ser Leu Pro Ala
Ser Pro Ala Ile
Ser Pro Ala Leu
Ser Pro Ile Ala
Ser Pro Leu Ala
Thr Ala Pro Val
Thr Ala Val Pro
Thr Gly Ile Pro
Thr Gly Leu Pro
Thr Gly Pro Ile
Thr Gly Pro Leu
Thr Ile Gly Pro
Thr Ile Pro Gly
Thr Leu Gly Pro
Thr Leu Pro Gly
Thr Pro Ala Val
Thr Pro Gly Ile
Thr Pro Gly Leu
Thr Pro Ile Gly
Thr Pro Leu Gly
Thr Pro Val Ala
Thr Val Ala Pro
Thr Val Pro Ala
Val Ala Pro Thr
Val Ala Thr Pro
Val Pro Ala Thr
Val Pro Thr Ala
Val Thr Ala Pro
Val Thr Pro Ala
N-(2-aminoethyl)ethane-1,2-diamine,2-(chloromethyl)oxirane,hexanedioic acid,N-methylmethanamine
C15H35ClN4O5 (386.22958500000004)
butyl 2-methylprop-2-enoate,2-hydroxypropyl 2-methylprop-2-enoate,methyl 2-methylprop-2-enoate
1-Butyl-8-(3-noradamantyl)-3-(3-hydroxypropyl)xanthine
C21H30N4O3 (386.23177899999996)
PSB36 is a potent and selective antagonist of adenosine A1 receptor, with Kis 0.12 nM, 187 nM, 552 nM, 2300 nM, and 6500 nM for rA1, hA2B, rA2A, hA3 and rA3 receptors respectively. PSB36 can be used for the research of hyperalgesia[1][2].
N-(4,6-dimethyl-2-pyrimidinyl)-1,3-bis(phenylmethyl)-2,4-dihydro-1,3,5-triazin-6-amine
(8R)-8-({3,6-dideoxy-4-O-[(2E)-2-methylbut-2-enoyl]-alpha-L-arabino-hexopyranosyl}oxy)nonanoic acid
(1s,3r,4s,5s,7s)-4-{[2-(4-Methoxyphenoxy)-2-Methylpropanoyl]amino}adamantane-1-Carboxamide
(S)-N-(4-Carbamimidoylbenzyl)-1-(2-(Cyclohexyloxy)ethanoyl)pyrrolidine-2-Carboxamide
C21H30N4O3 (386.23177899999996)
(E)-7-[2-(1,2-dihydroxy-3-oxooctyl)-3,5-dihydroxycyclopentyl]hept-5-enoic acid
8-[4-(2,3-Dihydro-1,4-benzodioxin-3-ylmethylamino)butyl]-8-azaspiro[4.5]decane-7,9-dione
(4R,7R)-4-[(4-methoxyphenyl)methyl]-7-(2-methylpropyl)-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
C21H30N4O3 (386.23177899999996)
(4S,7S)-4-[(4-methoxyphenyl)methyl]-7-(2-methylpropyl)-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
C21H30N4O3 (386.23177899999996)
(5S,8S)-8-[(4-methoxyphenyl)methyl]-5-(2-methylpropyl)-3-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-7-one
C21H30N4O3 (386.23177899999996)
(4S,7R)-4-[(4-methoxyphenyl)methyl]-7-(2-methylpropyl)-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
C21H30N4O3 (386.23177899999996)
(4R,7S)-4-[(4-methoxyphenyl)methyl]-7-(2-methylpropyl)-9-oxa-1,6,12,13-tetrazabicyclo[9.2.1]tetradeca-11(14),12-dien-5-one
C21H30N4O3 (386.23177899999996)
(5S,8R)-8-[(4-methoxyphenyl)methyl]-5-(2-methylpropyl)-3-oxa-1,6,13,14-tetrazabicyclo[9.3.0]tetradeca-11,13-dien-7-one
C21H30N4O3 (386.23177899999996)
[(1S)-1-[[(2R)-2-(1,4-dihydropyrazine-2-carbonylamino)-3-phenylpropanoyl]amino]-3-methylbutyl]boronic acid
6-[4-[1-[(3S)-3-hydroxycyclohexyl]-2H-tetrazol-1-ium-5-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
C20H28N5O3+ (386.21920380000006)
(5S,6Z,8E,12S,14Z)-5,12,20,20,20-pentahydroxyicosa-6,8,14-trienoic acid
(4S)-6-[4-(1-cyclohexyl-2H-tetrazol-1-ium-5-yl)butoxy]-4-hydroxy-3,4-dihydro-1H-quinolin-2-one
C20H28N5O3+ (386.21920380000006)
6-[4-[1-(3-hydroxycyclohexyl)-2H-tetrazol-1-ium-5-yl]butoxy]-3,4-dihydro-1H-quinolin-2-one
C20H28N5O3+ (386.21920380000006)
(1R,2S,5R)-5-Methyl-2-(1-methyl-1-(2-naphthyl)ethyl)-cyclohexane-1-YL benzoate
mbas#10
A 4-O-[(E)-2-methyl-2-butenoyl]ascaroside derived from (8R)-8-hydroxynonanoic acid. It is a metabolite of the nematode Caenorhabditis elegans.